Clopidogrel News and Research

RSS
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

University of Maryland researchers perform a  genome-wide association study of ADP-stimulated platelet aggregation

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Herbal supplements aren't always safe!

Herbal supplements aren't always safe!

FDA approves Effient (prasugrel) for heart attack in angioplasty patients

FDA approves Effient (prasugrel) for heart attack in angioplasty patients

Discovery of entirely new mechanism that promotes blood clot formation

Discovery of entirely new mechanism that promotes blood clot formation

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

Research may lead to new ways to fight clot formation

Research may lead to new ways to fight clot formation

Study looks at long-term benefits of the Wingspan stent

Study looks at long-term benefits of the Wingspan stent

Certain combined medications following heart attack may increase risk of death

Certain combined medications following heart attack may increase risk of death

Steroids and antihistamines alleviate clopidogrel-related allergic reaction symptoms

Steroids and antihistamines alleviate clopidogrel-related allergic reaction symptoms

Drug-coated stents lower risk of heart attack and death

Drug-coated stents lower risk of heart attack and death

Clinical effectiveness of coronary stents in the elderly

Clinical effectiveness of coronary stents in the elderly

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

New drug derived from magnolia trees proves safe, tolerable in preventing blood clots

New drug derived from magnolia trees proves safe, tolerable in preventing blood clots

Best course of treatment to reduce risk of secondary stroke

Best course of treatment to reduce risk of secondary stroke

Certain combined medications after heart attack may increase risk of death

Certain combined medications after heart attack may increase risk of death

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Cell-coated stent as effective as drug-coated ones

Cell-coated stent as effective as drug-coated ones